523 678

Cited 11 times in

Cited 14 times in

Microparticles derived from human erythropoietin mRNA-transfected mesenchymal stem cells inhibit epithelial-to-mesenchymal transition and ameliorate renal interstitial fibrosis

DC Field Value Language
dc.contributor.authorLee, Mirae-
dc.contributor.authorKim, Seok-hyung-
dc.contributor.authorJhee, Jong Hyun-
dc.contributor.authorKim, Tae Yeon-
dc.contributor.authorChoi, Hoon Young-
dc.contributor.authorKim, Hyung Jong-
dc.contributor.authorPark, Hyeong Cheon-
dc.date.accessioned2020-12-01T17:03:13Z-
dc.date.available2020-12-01T17:03:13Z-
dc.date.created2021-03-18-
dc.date.issued2020-09-
dc.identifier.issn1757-6512-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/180101-
dc.description.abstractBackgroundRenal tubulointerstitial fibrosis (TIF) plays an important role in the progression of chronic kidney disease (CKD) and its pathogenesis involves epithelial-to-mesenchymal transition (EMT) upon renal injury. Recombinant human erythropoietin (rhEPO) has been shown to display novel cytoprotective effects, in part by inhibiting transforming growth factor (TGF)-beta 1-induced EMT. Here, we evaluated the inhibitory effects of microparticles (MPs) derived from human EPO gene-transfected kidney mesenchymal stem cells (hEPO-KMSCs) against TGF-beta 1-induced EMT in Madin-Darby canine kidney (MDCK) cells and against TIF in mouse kidneys with unilateral ureteral obstruction (UUO).MethodsEMT was induced in MDCK cells by treatment with TGF-beta 1 (5ng/mL) for 48h and then inhibited by co-treatment with rhEPO (100IU/mL), mock gene-transfected KMSC-derived MPs (MOCK-MPs), or hEPO-KMSC-derived MPs (hEPO-MPs) for a further 48h. UUO was induced in FVB/N mice, which were then treated with rhEPO (1000IU/kg, intraperitoneally, every other day for 1week), MOCK-MPs, or hEPO-MPs (80 mu g, intravenously). Alpha-smooth muscle actin (alpha -SMA), fibronectin, and E-cadherin expression were evaluated in MDCK cells and kidney tissues, and the extent of TIF in UUO kidneys was assessed by immunohistochemical staining.ResultsTGF-beta 1 treatment significantly increased alpha -SMA and fibronectin expression in MDCK cells and decreased that of E-cadherin, while co-treatment with rhEPO, MOCK-MPs, or hEPO-MPs markedly attenuated these changes. In addition, rhEPO and hEPO-MP treatment effectively decreased phosphorylated Smad2 and Smad3, as well as phosphorylated p38 mitogen-activated protein kinase (MAPK) expression, suggesting that rhEPO and rhEPO-MPs can inhibit TGF-beta 1-induced EMT via both Smad and non-Smad pathways. rhEPO and hEPO-MP treatment also significantly attenuated the extent of renal TIF after 1week of UUO compared to MOCK-MPs, with hEPO-MPs significantly reducing myofibroblast and F4/80+ macrophage infiltration as well as EMT marker expression in UUO renal tissues in a similar manner to rhEPO.ConclusionsOur results demonstrate that hEPO-MPs modulate TGF-beta 1-induced EMT in MDCK cells via the Smad2, Smad3, and p38 MAPK pathways and significantly attenuated renal TIF in UUO kidneys.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherBioMed Central-
dc.relation.isPartOfSTEM CELL RESEARCH & THERAPY-
dc.relation.isPartOfSTEM CELL RESEARCH & THERAPY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleMicroparticles derived from human erythropoietin mRNA-transfected mesenchymal stem cells inhibit epithelial-to-mesenchymal transition and ameliorate renal interstitial fibrosis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorLee, Mirae-
dc.contributor.googleauthorKim, Seok-hyung-
dc.contributor.googleauthorJhee, Jong Hyun-
dc.contributor.googleauthorKim, Tae Yeon-
dc.contributor.googleauthorChoi, Hoon Young-
dc.contributor.googleauthorKim, Hyung Jong-
dc.contributor.googleauthorPark, Hyeong Cheon-
dc.identifier.doi10.1186/s13287-020-01932-z-
dc.relation.journalcodeJ02681-
dc.identifier.eissn1757-6512-
dc.subject.keywordMicroparticles-
dc.subject.keywordTransforming growth factor-beta 1-
dc.subject.keywordRenal fibrosis-
dc.subject.keywordEpithelial-to-mesenchymal transition-
dc.subject.keywordErythropoietin-
dc.contributor.alternativeNameKim, Seok Hyung-
dc.contributor.affiliatedAuthorKim, Seok-hyung-
dc.contributor.affiliatedAuthorJhee, Jong Hyun-
dc.contributor.affiliatedAuthorChoi, Hoon Young-
dc.contributor.affiliatedAuthorPark, Hyeong Cheon-
dc.identifier.scopusid2-s2.0-85092284133-
dc.identifier.wosid000576926800002-
dc.citation.volume11-
dc.citation.number1-
dc.identifier.bibliographicCitationSTEM CELL RESEARCH & THERAPY, Vol.11(1), 2020-09-
dc.identifier.rimsid68840-
dc.type.rimsART-
dc.description.journalClass1-
dc.description.journalClass1-
dc.subject.keywordAuthorMicroparticles-
dc.subject.keywordAuthorTransforming growth factor-beta 1-
dc.subject.keywordAuthorRenal fibrosis-
dc.subject.keywordAuthorEpithelial-to-mesenchymal transition-
dc.subject.keywordAuthorErythropoietin-
dc.subject.keywordPlusSTROMAL CELLS-
dc.subject.keywordPlusTGF-BETA-
dc.subject.keywordPlusREGENERATIVE MEDICINE-
dc.subject.keywordPlusDARBEPOETIN-ALPHA-
dc.subject.keywordPlusKIDNEY-
dc.subject.keywordPlusMICROVESICLES-
dc.subject.keywordPlusMECHANISMS-
dc.subject.keywordPlusPROTECT-
dc.subject.keywordPlusANEMIA-
dc.subject.keywordPlusINJURY-
dc.type.docTypeArticle-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalWebOfScienceCategoryCell & Tissue Engineering-
dc.relation.journalWebOfScienceCategoryCell Biology-
dc.relation.journalWebOfScienceCategoryMedicine, Research & Experimental-
dc.relation.journalResearchAreaCell Biology-
dc.relation.journalResearchAreaResearch & Experimental Medicine-
dc.identifier.articleno422-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.